行为经济需求在人类虐待潜在评估中的应用:综述和对未来测试的建议。

IF 1.6 3区 医学 Q3 PHARMACOLOGY & PHARMACY
Justin C Strickland, Derek D Reed, Mikhail N Koffarnus, Samuel F Acuff, Brett W Gelino, Madison E Graham, Brent A Kaplan, Alexandra Johansen, Zachary Pierce-Messick, Matthew L Banks, S Stevens Negus, David N Kearns, Dominic Chiapperino, Chad J Reissig, Neil B Varshneya, Steven R Hursh
{"title":"行为经济需求在人类虐待潜在评估中的应用:综述和对未来测试的建议。","authors":"Justin C Strickland, Derek D Reed, Mikhail N Koffarnus, Samuel F Acuff, Brett W Gelino, Madison E Graham, Brent A Kaplan, Alexandra Johansen, Zachary Pierce-Messick, Matthew L Banks, S Stevens Negus, David N Kearns, Dominic Chiapperino, Chad J Reissig, Neil B Varshneya, Steven R Hursh","doi":"10.1037/pha0000877","DOIUrl":null,"url":null,"abstract":"<p><p>A key step in the regulatory evaluation of new chemical entities is the assessment of their abuse potential. Human abuse potential (HAP) studies provide insights into the likelihood that new chemical entities have the potential for intentional, nonmedical use and therefore should be considered for greater regulatory control. Behavioral economic demand methods are proposed as a complementary method to improve the resolution of abuse liability testing. These procedures are posited to provide scalar, rank-ordered comparisons of abuse potential that are comparable across drugs and to better model real-world contexts in which constraint and cost influence drug-taking potential. The current review considers the applicability of behavioral economic demand methods to HAP testing frameworks. We review existing studies that have applied procedures broadly consistent with HAP testing and integrated demand procedures to measure abuse potential and/or a drug reinforcement. Procedural details and the demand methods implemented are reviewed toward the goal of informing the methods for applying demand testing in the HAP study framework and the existing gaps in defining those methods. Ultimately, efforts to improve the sensitivity and resolution of assays to detect and differentiate abuse potential stand to improve public health by concentrating efforts on the adequate control of drugs that pose risk while minimizing the restrictions on those with a lower abuse potential to maximize their clinical utility. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>","PeriodicalId":12089,"journal":{"name":"Experimental and clinical psychopharmacology","volume":" ","pages":""},"PeriodicalIF":1.6000,"publicationDate":"2026-08-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519940/pdf/","citationCount":"0","resultStr":"{\"title\":\"The use of behavioral economic demand in human abuse potential assessment: A review and recommendations for future testing.\",\"authors\":\"Justin C Strickland, Derek D Reed, Mikhail N Koffarnus, Samuel F Acuff, Brett W Gelino, Madison E Graham, Brent A Kaplan, Alexandra Johansen, Zachary Pierce-Messick, Matthew L Banks, S Stevens Negus, David N Kearns, Dominic Chiapperino, Chad J Reissig, Neil B Varshneya, Steven R Hursh\",\"doi\":\"10.1037/pha0000877\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A key step in the regulatory evaluation of new chemical entities is the assessment of their abuse potential. Human abuse potential (HAP) studies provide insights into the likelihood that new chemical entities have the potential for intentional, nonmedical use and therefore should be considered for greater regulatory control. Behavioral economic demand methods are proposed as a complementary method to improve the resolution of abuse liability testing. These procedures are posited to provide scalar, rank-ordered comparisons of abuse potential that are comparable across drugs and to better model real-world contexts in which constraint and cost influence drug-taking potential. The current review considers the applicability of behavioral economic demand methods to HAP testing frameworks. We review existing studies that have applied procedures broadly consistent with HAP testing and integrated demand procedures to measure abuse potential and/or a drug reinforcement. Procedural details and the demand methods implemented are reviewed toward the goal of informing the methods for applying demand testing in the HAP study framework and the existing gaps in defining those methods. Ultimately, efforts to improve the sensitivity and resolution of assays to detect and differentiate abuse potential stand to improve public health by concentrating efforts on the adequate control of drugs that pose risk while minimizing the restrictions on those with a lower abuse potential to maximize their clinical utility. (PsycInfo Database Record (c) 2026 APA, all rights reserved).</p>\",\"PeriodicalId\":12089,\"journal\":{\"name\":\"Experimental and clinical psychopharmacology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2026-08-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13519940/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Experimental and clinical psychopharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1037/pha0000877\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Experimental and clinical psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1037/pha0000877","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

摘要

对新化学实体进行监管评价的一个关键步骤是评估其滥用潜力。人体滥用潜力(HAP)研究提供了对新化学实体有可能被有意、非医疗使用的可能性的见解,因此应考虑加强监管控制。提出了行为经济需求法作为改进滥用责任检验解决方案的补充方法。这些程序的目的是提供各种药物之间可比较的滥用潜力的标量、按等级排序的比较,并更好地模拟约束和成本影响吸毒潜力的现实环境。本文考虑了行为经济需求方法在HAP测试框架中的适用性。我们回顾了现有的研究,这些研究采用了与HAP测试大致一致的程序和综合需求程序来衡量滥用潜力和/或药物强化。本文回顾了程序细节和实施的需求方法,目的是为在HAP研究框架中应用需求测试的方法提供信息,以及在定义这些方法方面存在的差距。最终,努力提高检测和区分滥用可能性的检测方法的灵敏度和分辨率,有助于改善公众健康,集中力量充分控制构成风险的药物,同时尽量减少对滥用可能性较低的药物的限制,以最大限度地发挥其临床效用。(PsycInfo数据库记录(c) 2026 APA,版权所有)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The use of behavioral economic demand in human abuse potential assessment: A review and recommendations for future testing.

A key step in the regulatory evaluation of new chemical entities is the assessment of their abuse potential. Human abuse potential (HAP) studies provide insights into the likelihood that new chemical entities have the potential for intentional, nonmedical use and therefore should be considered for greater regulatory control. Behavioral economic demand methods are proposed as a complementary method to improve the resolution of abuse liability testing. These procedures are posited to provide scalar, rank-ordered comparisons of abuse potential that are comparable across drugs and to better model real-world contexts in which constraint and cost influence drug-taking potential. The current review considers the applicability of behavioral economic demand methods to HAP testing frameworks. We review existing studies that have applied procedures broadly consistent with HAP testing and integrated demand procedures to measure abuse potential and/or a drug reinforcement. Procedural details and the demand methods implemented are reviewed toward the goal of informing the methods for applying demand testing in the HAP study framework and the existing gaps in defining those methods. Ultimately, efforts to improve the sensitivity and resolution of assays to detect and differentiate abuse potential stand to improve public health by concentrating efforts on the adequate control of drugs that pose risk while minimizing the restrictions on those with a lower abuse potential to maximize their clinical utility. (PsycInfo Database Record (c) 2026 APA, all rights reserved).

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.20
自引率
8.70%
发文量
164
审稿时长
6-12 weeks
期刊介绍: Experimental and Clinical Psychopharmacology publishes advances in translational and interdisciplinary research on psychopharmacology, broadly defined, and/or substance abuse.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书